ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0821

Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis

Susanne Pedersen1, Ulrich Weber2, Ozun Bayindir Tsechelidis3, Robert Lambert4, Joel Paschke5, Stephanie Wichuk4 and Walter Maksymowych4, 1Rigshospitalet, København, Denmark, 2Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, 3Ottawa University, Ottawa, ON, Canada, 4University of Alberta, Edmonton, AB, Canada, 5CARE Arthritis, Edmonton, AB, Canada

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), Diagnostic criteria, Magnetic resonance imaging (MRI), spondyloarthritis, Spondyloarthropathies

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Recent analysis of MRI scans from the 2009 ASAS classification cohort has led to a new proposal for the application of more stringent MRI inflammatory and structural lesion cut-offs for defining a positive MRI aimed at higher specificity. The cut-offs are based on numbers of sacroiliac joint quadrants with the affected lesion, being ≥3 for erosion (ER), ≥4 for bone marrow edema (BME), ≥5 for fat lesion (FAT), and ≥2 for deep fat lesion extending ≥1cm from subchondral bone1. We aimed to validate the performance of these cut-offs in patients with axSpA according to different clinical phenotypes encompassing patients with concomitant psoriasis (PsO), acute anterior uveitis (AAU), and inflammatory bowel disease (IBD). Our comparator was age- and gender-matched mechanical back pain controls diagnosed with non-axSpA.

Methods: Patients diagnosed with axial spondyloarthritis (axSpA) and fulfilling the modified New York criteria (mNY) were included from a prospective, observational cohort (ALBERTA FORCAST). All axSpA cases with AAU, PsO, or IBD, diagnosed by an ophthalmologist, dermatologist, or gastroenterologist, or axSpA alone with no extra-articular features, and with available MRI SIJ scans (semicoronal T1W, STIR), were matched for age and gender with scans from non-axSpA controls. MRI active and structural lesions per ASAS definitions2 were evaluated by 3 readers blinded to clinical details and recorded in the ASAS MRImagine-consensus based eCRF that comprised global assessment (MRI indicative of axSpA, active or structural lesion typical of axSpA present/absent) and detailed scoring of lesions per SIJ quadrant or halves (SPARCC method). We also assessed the utility of definite sclerosis (SCL), defined as dark signal on MRI that extends continuously ≥0.5cm in horizontal depth. Cut-offs for backfill (BF), and ankylosis (ANK) were assessed according to number of SIJ halves. Sensitivity and specificity of MRI cut-offs from ≥2 to ≥5 SIJ quadrants (for BME, ER, FAT, SCL) or halves (BF, ANK) with diagnosis of axSpA as gold standard, were analyzed.

Results: Scans were available from 44, 45, 27, 45, axSpA patients with PsO, AAU, IBD, or axSpA alone and 78 matched non-axSpA controls. For BME, a substantial increase in specificity was evident with a cut-off ≥4 at 92.3% with limited impact on sensitivity for diagnosis of axSpA among all subgroups when compared to a cut-off ≥3 (Table). For ER, specificity was 96.2% at a cut-off ≥3 with limited impact on sensitivity when compared to a cut-off ≥2. For FAT, specificity was 94.9% at a cut-off ≥5 with limited impact on sensitivity when compared to a cut-off ≥4, while a deep fat lesion already had high specificity of 96.2% even at a cut-off ≥2. BF and ANK had 100% specificity at cut-offs of ≥2 while SCL had high specificity, but sensitivity was low even at the cut-off ≥2.

Conclusion: The data-driven MRI lesion cut-offs demonstrated high performance characteristics, supporting the validity of the preliminary ASAS Data-Driven MRI lesion cut-offs.

< ![if !supportLists] >1.        < ![endif] >Maksymowych et al. Rheumatol 2021;60:4778–4789

< ![if !supportLists] >2.        < ![endif] >Maksymowych et al. Ann Rheum Dis 2019;78:1550-1558

Supporting image 1

Table. Sensitivity and Specificity of MRI cut-offs for SIJ lesions for axSpA subgroups.


Disclosures: S. Pedersen: AbbVie/Abbott, 6, Innovation Fund Denmark, 5, Merck/MSD, 6, Nordic Bioscience, 5, Novartis, 2, 5, 6, Pfizer, 6, UCB, 6; U. Weber: AbbVie, 6, Eli-Lilly, 2, 6, Novartis, 2, 6; O. Bayindir Tsechelidis: Janssen, 5; R. Lambert: CARE Arthritis, 2, Image Analysis Group, 2; J. Paschke: CARE Arthritis Limited, 3; S. Wichuk: None; W. Maksymowych: AbbVie, 2, 5, 6, Boehringer Ingelheim, 2, 6, Bristol Myers Squibb (BMS), 2, 6, CARE Arthritis Limited, 4, Celgene, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB Pharma, 2, 5, 6.

To cite this abstract in AMA style:

Pedersen S, Weber U, Bayindir Tsechelidis O, Lambert R, Paschke J, Wichuk S, Maksymowych W. Validation of ASAS Preliminary Data-Driven MRI Lesion Cut-offs for a Positive MRI of the Sacroiliac Joints in Patients with Axial Spondyloarthritis and Subgroups with Psoriasis, Iritis, and Colitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/validation-of-asas-preliminary-data-driven-mri-lesion-cut-offs-for-a-positive-mri-of-the-sacroiliac-joints-in-patients-with-axial-spondyloarthritis-and-subgroups-with-psoriasis-iritis-and-colitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-asas-preliminary-data-driven-mri-lesion-cut-offs-for-a-positive-mri-of-the-sacroiliac-joints-in-patients-with-axial-spondyloarthritis-and-subgroups-with-psoriasis-iritis-and-colitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology